This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011–24.

Published: 26th April 2017

Authors: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al.

Conclusion

In this study that included 730 patients, the addition of capecitabine improved median survival from 25.5 to 28 months (hazard ratio 0.82, 95 per cent confidence interval 0.68 to 0.98, P=0.032).

You may also be interested in

Scientific Surgery

Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020; 9: 1129.

Authors: Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A et al.

Scientific Surgery

FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406.

Authors: Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul J-L et al.

Scientific Surgery

Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018; 268: 215-222.

Authors: Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H et al.

Scientific Surgery

CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 2017; 35: 3330-3337.

Authors: Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W et al.

Scientific Surgery

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248–25716.

Authors: Uesaka K, Boku N, Kukutomi A, Okamura Y, Knoishi M, Matsumoto I et al.

Scientific Surgery

Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481.

Authors: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K et al. et al.

Scientific Surgery

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147–156.

Authors: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC et al. et al.

Scientific Surgery

Open-label, multicentre, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012; 30: 4077–4083.

Authors: Schmidt J, Abel U, Debus J, Harig S, Hoffman K, Herrmann T et al. et al.

Scientific Surgery

Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J Surg 2012; 36: 1016-1029.

Authors: Coughlin S, Roth L, Lurati G, Faulhaber M

Scientific Surgery

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105–4112.

Authors: Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D et al.

Scientific Surgery

Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29: 3541–3546.

Authors: Wyse JM, Carone M, Paquin SC, Usatill M, Sahai AV

Scientific Surgery

Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.

Authors: Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al. et al.